NCT03801369 2026-02-25
AMTEC IIT: Phase 2 Multiarm Study in TNBC
OHSU Knight Cancer Institute
Phase 2 Terminated
Clinical Trials
9 trialsNCT03095248 2025-04-22
SEL-TH-1601
Children's Hospital Medical Center, Cincinnati
Phase 2 Terminated
NCT01256359 2024-08-15
DOC-MEK
University of Oxford
Phase 2 Completed
NCT02393690 2024-07-26
Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer
Academic and Community Cancer Research United
Phase 2 Completed
NCT01248247 2022-01-12
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01586624 2021-10-07
A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)
Cancer Research UK
Phase 1 Completed
NCT00780676 2020-09-03
Personalized Treatment Selection for Metastatic Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00970359 2017-04-12
Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT01313039 2017-02-07
Evaluation of the Use of AZD6244 to Induce Increased ER Expression and Anti-Estrogen Response in ER-Negative/Low Breast Cancer
University of Miami
Phase EARLY_PHASE1 Completed